Mizuho Markets Cayman LP Buys New Shares in NewAmsterdam Pharma Company N.V. $NAMS

Mizuho Markets Cayman LP purchased a new stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 47,879 shares of the company’s stock, valued at approximately $1,680,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its holdings in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the last quarter. Navalign LLC bought a new stake in NewAmsterdam Pharma in the 4th quarter valued at $46,000. NBC Securities Inc. bought a new stake in NewAmsterdam Pharma in the 4th quarter valued at $86,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in NewAmsterdam Pharma by 26.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock valued at $193,000 after acquiring an additional 1,156 shares during the last quarter. Finally, Simon Quick Advisors LLC bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth about $202,000. 89.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the completion of the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $2,099,850.60. The trade was a 60.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael H. Davidson sold 443,707 shares of NewAmsterdam Pharma stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This represents a 71.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 1,122,805 shares of company stock valued at $36,606,033. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Stock Down 0.8%

NewAmsterdam Pharma stock opened at $35.44 on Friday. The company’s 50-day moving average price is $32.76 and its 200-day moving average price is $34.25. NewAmsterdam Pharma Company N.V. has a twelve month low of $16.78 and a twelve month high of $42.21. The company has a market cap of $4.14 billion, a PE ratio of -19.80 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. As a group, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on NAMS shares. Guggenheim boosted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Truist Financial started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price on the stock. Needham & Company LLC boosted their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $48.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.